Rhythm Pharmaceuticals announced that seven presentations, including four late-breaking abstracts, have been accepted for The Endocrine Society's Annual Meeting (ENDO 2026) in Chicago from June 13-16, 2026. The presentations will showcase clinical trial data for setmelanotide and bivamelagon in treating rare neuroendocrine diseases including Prader-Willi syndrome, acquired hypothalamic obesity, and Bardet-Biedl syndrome. The company will also host its inaugural MOMENTUM meeting on June 12 to discuss advances in MC4R pathway diseases.

Rhythm Pharmaceuticals announced that its Chairman, President and CEO David Meeker and CFO Hunter Smith will participate in fireside chats at the Jefferies Global Healthcare Conference (June 4, 2026) and Goldman Sachs 47th Annual Global Healthcare Conference (June 8, 2026), respectively. The company's lead asset IMCIVREE (setmelanotide) is an FDA-approved MC4R agonist for treating rare obesity conditions including acquired hypothalamic obesity and genetic syndromes like Bardet-Biedl syndrome.

Green Thumb Industries has filed for DEA registration following the rescheduling of marijuana to Schedule III, positioning itself as a first-mover in the evolving U.S. cannabis landscape. The move could attract institutional investors, enable research partnerships, and potentially lead to major stock exchange listings if recreational cannabis is also rescheduled. CEO Ben Kovler emphasized that this strategic action normalizes the federal cannabis industry.

Rhythm Pharmaceuticals announced the appointment of Kim Popovits, an accomplished life sciences leader with 40+ years of experience, to its Board of Directors, replacing departing board member Ed Mathers who served since 2013. Popovits brings extensive expertise in commercialization, reimbursement, and governance from her previous roles at Genomic Health and Genentech.

Rhythm Pharmaceuticals announced FDA approval of IMCIVREE (setmelanotide) for acquired hypothalamic obesity, becoming the first and only FDA-approved therapy for this rare disease. The approval is based on Phase 3 TRANSCEND trial results showing an 18.4% placebo-adjusted BMI reduction in 142 patients. The drug is indicated for adults and pediatric patients aged 4 years and older.

U.S. stock futures declined on Tuesday following geopolitical tensions over the Strait of Hormuz, with major indices down 0.43-0.84%. European allies rejected Trump's call to deploy naval forces. Oil prices rose 4.72% amid supply concerns. Key movers included Uber (up on NVIDIA partnership), Lululemon (awaiting earnings), Cisco (down despite AI expansion), and Comtech (down 9.64% on mixed results). The Fed is expected to maintain rates unchanged in March.

Rhythm Pharmaceuticals announced that its EMANATE Phase 3 trial for setmelanotide failed to meet primary endpoints for treating rare genetic obesity. While post hoc analyses showed statistically significant BMI reductions in specific patient subgroups and the safety profile remained consistent, the stock declined 4.98% to $86.00. The company plans to shift focus to next-generation MC4R agonists and continue analyzing the dataset.

Rhythm Pharmaceuticals announced positive Phase 3 TRANSCEND trial data for setmelanotide in acquired hypothalamic obesity, showing an 18.8% placebo-adjusted BMI reduction difference across 142 patients at 52 weeks. The company's supplemental New Drug Application (sNDA) is under FDA review with a PDUFA goal date of March 20, 2026, and the company also plans regulatory submissions in Europe and Japan.

Rhythm Pharmaceuticals reported promising early Phase 2 trial results for setmelanotide in treating Prader-Willi syndrome, with potential therapeutic benefits in reducing BMI and extreme hunger. The company plans to advance to a Phase 3 trial and has initiated a new trial arm for a MC4R agonist.

Eli Lilly and Novo Nordisk are preparing to launch oral obesity treatment pills in 2026, with pricing expected to match existing injectable drugs, despite some underwhelming clinical trial data showing modest weight loss results.

Rhythm Pharmaceuticals reported strong Q1 2025 results, with $37.7 million in net product revenue from IMCIVREE and positive data from its pivotal Phase 3 trial of setmelanotide in acquired hypothalamic obesity. The company also provided updates on its pipeline and anticipated upcoming milestones.

Rhythm Pharmaceuticals announced positive topline results from its pivotal Phase 3 TRANSCEND trial evaluating setmelanotide for the treatment of acquired hypothalamic obesity. The trial met its primary endpoint with a statistically significant and clinically meaningful reduction in body mass index (BMI) with setmelanotide compared to placebo in both adult and pediatric patients.